| Compounds | Topics | Title | Date |
|---|---|---|---|
| Bisabolol | cancer in vitro via experiment | Pro-apoptotic activity of Alpha-bisabolol in preclinical models of primary human acute leukemia cells | Nov 2010 |
| Our study provides the first evidence that alpha--bisabolol is a pro-apoptotic agent for primary human acute leukemia cells. | |||
| Bisabolol | anti-oxidant in vitro | Antioxidant activity of bisabolol: inhibitory effects on chemiluminescence of human neutrophil bursts and cell-free systems. | Dec 2008 |
| These findings draw the attention to the possible medical use of bisabolol as a means of improving the antioxidant network and restoring the redox balance by antagonising oxidative stress. | |||
| Bisabolol | anti-inflamatory in vitro | Inhibitory effects of (-)-Alpha-bisabolol on LPS-induced inflammatory response in RAW264.7 macrophages. | Oct 2011 |
| Our results indicate that (-)-alpha--bisabolol exerts anti-inflammatory effects by downregulating expression of iNOS and COX-2 genes through inhibition of NF-kappa-B and AP-1 (ERK and p38) signaling. | |||
| Bisabolol | anti-inflamatory,pain in mice via model | Anti-nociceptive and anti-inflammatory activities of (-)-Alpha-bisabolol in rodents. | Dec 2011 |
| These findings suggest that the anti-nociceptive action of (-)-alpha--bisabolol is not linked to a central mechanism but instead is related to the inflammatory process. | |||
| Bisabolol | anti-viral in vitro | The antimicrobial activity of alpha-bisabolol and tea tree oil against Solobacterium moorei, a Gram-positive bacterium associated with halitosis. | Jan 2013 |
| Halitosis-associated bacterium S. moorei is susceptible to the antimicrobial agents tea tree oil and alpha-bisabolol, suggesting that these compounds might be beneficial in oral healthcare products. | |||
| Bisabolol | anti-inflamatory in vitro | Alpha-(-)-bisabolol reduces pro-inflammatory cytokine production and ameliorates skin inflammation. | 2014 |
| These findings suggested that alpha--(-)-bisabolol may be a useful therapeutic candidate for the treatment of skin inflammation. | |||
| Bisabolol | anti-bacterial in mice via experiment | (-)-Alpha-Bisabolol, a Promising Oral Compound for the Treatment of Visceral Leishmaniasis | June 2015 |
|
Ingestion Method: oral Bisabolol is a nontoxic compound that was proven to be active against visceral leishmaniasis in an in vivo murine model orally. | |||
| Bisabolol | leg ulcers in humans via placebo trial (n=29) | Randomized, controlled study of innovative spray formulation containing ozonated oil and Alpha-bisabolol in the topical treatment of chronic venous leg ulcers. | Sep 2015 |
|
Ingestion Method: topical At the end of treatment, the proportion of patients with complete ulcer healing was higher with ozonated oil and alpha--bisabolol formulation (25% vs 0%). Furthermore, the changes in ulcer surface area were significant for ozonated oil and alpha--bisabolol formulation only (P < .05), in particular, observing a significant and progressive reduction of the wound surface by 34%, 59%, and 73%, after 7, 14, and 30 days of treatment, respectively. | |||
| Bisabolol | cancer in rats via placebo trial | Bisabolol ameliorates cisplatin-induced nephrotoxicity in rats | Jan 2015 |
| Based on present study findings, it can be concluded that BSB may be an excellent therapeutic agent to prevent CSP-induced nephrotoxicity. Given the wide beneficial effects and safety profile of BSB along with its antitumorigenic activity, BSB has tremendous therapeutic potential in a multitude of other diseases associated with inflammation and oxidative stress. | |||